Patents by Inventor Robert W. Finberg
Robert W. Finberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9493538Abstract: The present invention provides a snare molecules comprising an attachment moiety (which facilitates attachment of a receptor to a cell) and a receptor for a toxic pathogenic or infectious agent, e.g., a virus. Methods of producing such snare molecules and their therapeutic and/or prophylactic uses are also provided by the present invention.Type: GrantFiled: May 27, 2005Date of Patent: November 15, 2016Assignee: UNIVERSITY OF MASSACHUSETTSInventors: Robert W. Finberg, Damon R. Asher
-
Patent number: 9271972Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.Type: GrantFiled: November 14, 2013Date of Patent: March 1, 2016Assignee: University of MassachusettsInventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
-
Publication number: 20140296219Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.Type: ApplicationFiled: November 14, 2013Publication date: October 2, 2014Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
-
Patent number: 8748403Abstract: Toll-like receptor 2 (TLR2) has been found to mediate certain effects of HSV infection, particularly in neonates. Compounds that decrease TLR2 expression or activity are useful for ameliorating such deleterious effects.Type: GrantFiled: January 21, 2005Date of Patent: June 10, 2014Assignee: University of MassachusettsInventors: Evelyn A. Kurt-Jones, Robert W. Finberg
-
Patent number: 8609663Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.Type: GrantFiled: November 17, 2010Date of Patent: December 17, 2013Assignee: University of MassachusettsInventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
-
Patent number: 8231861Abstract: The present invention provides methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis.Type: GrantFiled: November 19, 2004Date of Patent: July 31, 2012Assignee: University of MassachusettsInventors: Ashok Saluja, Rifat Sharif, Evelyn A. Kurt-Jones, Robert W. Finberg
-
Publication number: 20110152251Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.Type: ApplicationFiled: November 17, 2010Publication date: June 23, 2011Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
-
Patent number: 7759465Abstract: It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere with signaling through TLR1/TLR2 complexes.Type: GrantFiled: June 6, 2008Date of Patent: July 20, 2010Assignee: University of MassachusettsInventors: Evelyn A. Kurt-Jones, Robert W. Finberg
-
Publication number: 20090087430Abstract: It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere with signaling through TLR1/TLR2 complexes.Type: ApplicationFiled: June 6, 2008Publication date: April 2, 2009Inventors: Evelyn A. Kurt-Jones, Robert W. Finberg
-
Patent number: 7405342Abstract: The present invention is directed, at least in part, to mice which express exogenous complement receptor type 1 (CR1) on red blood cells. The invention also pertains to genetic constructs encoding heterologous CR1 for expression on red blood cells. Methods of using the transgenic animals of the invention to identify and/or evaluate compositions that can reduce the concentration of an agent, e.g., a biologic agent, in the serum, circulation and/or tissues of a subject are also provided.Type: GrantFiled: May 10, 2004Date of Patent: July 29, 2008Assignee: University of MassachusettsInventor: Robert W. Finberg
-
Patent number: 7388080Abstract: It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere with signaling through TLR1/TLR2 complexes.Type: GrantFiled: August 20, 2004Date of Patent: June 17, 2008Assignee: University of MassachusettsInventors: Evelyn A. Kurt-Jones, Robert W. Finberg
-
Publication number: 20080112887Abstract: The present invention provides methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis.Type: ApplicationFiled: November 19, 2004Publication date: May 15, 2008Inventors: Ashok Saluja, Rifat Sharif, Evelyn A. Kurt-Jones, Robert W. Finberg
-
Patent number: 6949507Abstract: The present invention provides for the use of G protein binding agents for prophylactic and/or therapeutic treatments of septic shock. The present invention provides methods of using agents which bind G protein to treat a subject having or susceptible to septic shock. The present invention further pertains to compositions for treating a subject for septic shock. The composition includes an effective amount of a G protein binding agent and, optionally, an antibiotic and a pharmaceutically acceptable carrier. Other aspects of the invention include packaged agents which bind G proteins for treating septic shock.Type: GrantFiled: October 29, 2002Date of Patent: September 27, 2005Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Keith R. Solomon
-
Patent number: 6583110Abstract: The present invention provides for the use of G protein binding agents for prophylactic and/or therapeutic treatment of septic shock. The present invention provides methods of using agents which bind G protein to treat a subject having or susceptible to septic shock. The present invention further pertains to compositions for treating a subject for septic shock. The composition includes an effective amount of a G protein binding agent such as mastoparan and, optionally, an antibiotic and a pharmaceutically acceptable carrier. Other aspects of the invention include packaged agents which bind G proteins for treating septic shock.Type: GrantFiled: May 23, 2000Date of Patent: June 24, 2003Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Keith R. Solomon
-
Publication number: 20030069185Abstract: The present invention provides for the use of G protein binding agents for prophylactic and/or therapeutic treatments of septic shock. The present invention provides methods of using agents which bind G protein to treat a subject having or susceptible to septic shock. The present invention further pertains to compositions for treating a subject for septic shock. The composition includes an effective amount of a G protein binding agent and, optionally, an antibiotic and a pharmaceutically acceptable carrier. Other aspects of the invention include packaged agents which bind G proteins for treating septic shock.Type: ApplicationFiled: October 29, 2002Publication date: April 10, 2003Applicant: Dana-Farber Cancer InstituteInventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Keith R. Solomon
-
Patent number: 6210921Abstract: The invention provides isolated nucleic acid molecules which encode a coxsackievirus and adenovirus receptor protein, CAR. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CAR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CAR gene has been introduced or disrupted. The invention still further provides isolated CAR proteins, fusion proteins, antigenic peptides and anti-CAR antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: September 12, 1997Date of Patent: April 3, 2001Inventors: Robert W. Finberg, Jeffrey M. Bergelson, Marshall S. Horwitz
-
Patent number: 5753516Abstract: This invention relates primarily to opioid binding proteins specifically, the invention relates to lymphocyte-specific opioid recognition sites and methods and compositions related to them. For example, methods of determining agonists and antagonists of immune cell-specific opioid binding protein are presented.Type: GrantFiled: February 3, 1995Date of Patent: May 19, 1998Inventors: Wyrta E. Heagy, Robert W. Finberg
-
Patent number: 5019513Abstract: A method of protecting a mammal against a pathogenic bacterium by administering a soluble suppressor T-cell factor derived from a mammal that has been immunized with the bacterium or an antigenic surface fragment of the bacterium. Also disclosed are a hybrid cell fusion of an immunized suppressor T cell, methods of making such cells, and method of producing soluble suppressor T-cell factors.Type: GrantFiled: January 12, 1989Date of Patent: May 28, 1991Assignee: The Brigham and Women's Hospital, Inc.Inventors: Dennis L. Kasper, Dori F. Zaleznik, Robert W. Finberg